{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T06:03:18Z","timestamp":1794204198971,"version":"4.8.0"},"reference-count":45,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,8]]},"abstract":"<jats:p>Secretory carcinoma of the salivary glands, also known as mammary analogue secretory carcinoma, is a recently described tumor characterized by generally indolent clinical behavior and recurrent <jats:italic toggle=\"yes\">ETV6-NTRK3<\/jats:italic> fusions. However, a small subset of recent cases with high-grade histology, aggressive behavior, or alternate molecular findings are expanding the spectrum of this entity. In this case, a 59-year-old female presented with an infiltrative submandibular gland tumor that was originally classified as a high-grade acinic cell carcinoma, papillary-cystic variant. She developed persistent local disease and, 11 years after initial presentation, was found to have widespread metastases. Rereview of her primary tumor highlighted microcystic, papillary, and solid architecture, eosinophilic cytoplasm, vesicular nuclei with prominent nucleoli, abundant mitotic figures, and necrosis. Immunostains showed the tumor cells to be positive for S100 and mammaglobin and negative for DOG-1, and fluorescence in situ hybridization highlighted an <jats:italic toggle=\"yes\">ETV6<\/jats:italic> rearrangement, supporting a diagnosis of high-grade secretory carcinoma. Finally, next-generation sequencing demonstrated a novel <jats:italic toggle=\"yes\">ETV6-MET<\/jats:italic> fusion. To our knowledge, this is the first <jats:italic toggle=\"yes\">ETV6-MET<\/jats:italic> fusion reported in secretory carcinoma. This finding further expands the definition of secretory carcinoma while carrying implications for selecting appropriate targeted therapy.<\/jats:p>","DOI":"10.1097\/pas.0000000000001065","type":"journal-article","created":{"date-parts":[[2018,4,20]],"date-time":"2018-04-20T22:47:46Z","timestamp":1524264466000},"page":"1121-1126","source":"Crossref","is-referenced-by-count":113,"title":["Salivary Secretory Carcinoma With a Novel ETV6-MET Fusion"],"prefix":"10.1097","volume":"42","author":[{"given":"Lisa M.","family":"Rooper","sequence":"first","affiliation":[{"name":"Pathology"},{"name":"Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodoros","family":"Karantanos","sequence":"additional","affiliation":[{"name":"Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Ning","sequence":"additional","affiliation":[{"name":"Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin A.","family":"Bishop","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah W.","family":"Gordon","sequence":"additional","affiliation":[{"name":"Department of Oncology, Virginia Commonwealth University, Richmond, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyunseok","family":"Kang","sequence":"additional","affiliation":[{"name":"Oncology"},{"name":"Otolaryngology, The Johns Hopkins Medical Institutions, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230922","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/PAS.0b013e3181d9efcc","article-title":"Mammary analogue secretory carcinoma of salivary glands, containing the ETV6-NTRK3 fusion gene: a hitherto undescribed salivary gland tumor entity","volume":"34","author":"Sk\u00e1lov\u00e1","year":"2010","journal-title":"Am J Surg Pathol"},{"key":"R2-20230922","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1097\/PAS.0b013e3182841554","article-title":"Most nonparotid \u201cacinic cell carcinomas\u201d represent mammary analog secretory carcinomas","volume":"37","author":"Bishop","year":"2013","journal-title":"Am J Surg Pathol"},{"key":"R3-20230922","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1365-2559.2012.04232.x","article-title":"Clinicopathological characterization of mammary analogue secretory carcinoma of salivary glands","volume":"61","author":"Chiosea","year":"2012","journal-title":"Histopathology"},{"key":"R4-20230922","doi-asserted-by":"crossref","first-page":"36","DOI":"10.4132\/KoreanJPathol.2013.47.1.36","article-title":"Finding and characterizing mammary analogue secretory carcinoma of the salivary gland","volume":"47","author":"Jung","year":"2013","journal-title":"Korean J Pathol"},{"key":"R5-20230922","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/modpathol.2013.84","article-title":"Searching for mammary analogue [corrected] secretory carcinoma of salivary gland among its mimics","volume":"27","author":"Pinto","year":"2014","journal-title":"Mod Pathol"},{"key":"R6-20230922","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/PAS.0b013e318242a5b0","article-title":"The profile of acinic cell carcinoma after recognition of mammary analog secretory carcinoma","volume":"36","author":"Chiosea","year":"2012","journal-title":"Am J Surg Pathol"},{"key":"R7-20230922","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/nbt.3080","article-title":"A comprehensive transcriptional portrait of human cancer cell lines","volume":"33","author":"Klijn","year":"2015","journal-title":"Nat Biotechnol"},{"key":"R8-20230922","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s00428-014-1701-8","article-title":"Mammary analogue secretory carcinoma of salivary glands: a new entity associated with ETV6 gene rearrangement","volume":"466","author":"Majewska","year":"2015","journal-title":"Virchows Arch"},{"key":"R9-20230922","first-page":"1497023","article-title":"Utility of Immunohistochemistry and ETV6 (12p13) gene rearrangement in identifying secretory carcinoma of salivary gland among previously diagnosed cases of acinic cell carcinoma","volume":"2017","author":"Naous","year":"2017","journal-title":"Patholog Res Int"},{"key":"R10-20230922","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.4317\/medoral.19874","article-title":"Mammary analogue secretory carcinoma (MASC) of salivary gland in four Mexican patients","volume":"20","author":"Serrano-Arevalo","year":"2015","journal-title":"Med Oral Patol Oral Cir Bucal"},{"key":"R11-20230922","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s12105-014-0557-1","article-title":"Morphology in conjunction with immunohistochemistry is sufficient for the diagnosis of mammary analogue secretory carcinoma","volume":"9","author":"Shah","year":"2015","journal-title":"Head Neck Pathol"},{"key":"R12-20230922","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.humpath.2014.09.012","article-title":"Characterization of mammary analogue secretory carcinoma of the salivary gland: discrimination from its mimics by the presence of the ETV6-NTRK3 translocation and novel surrogate markers","volume":"46","author":"Urano","year":"2015","journal-title":"Hum Pathol"},{"key":"R13-20230922","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/PAS.0b013e318231542a","article-title":"Mammary analog secretory carcinoma of salivary gland origin with the ETV6 gene rearrangement by FISH: expanded morphologic and immunohistochemical spectrum of a recently described entity","volume":"36","author":"Connor","year":"2012","journal-title":"Am J Surg Pathol"},{"key":"R14-20230922","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s00428-011-1098-6","article-title":"Mammary analogue secretory carcinoma: a new twist to the diagnostic dilemma of zymogen granule poor acinic cell carcinoma","volume":"459","author":"Griffith","year":"2011","journal-title":"Virchows Archiv"},{"key":"R15-20230922","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/j.prp.2017.07.017","article-title":"Clinicopathologic and molecular characterization of mammary analogue secretory carcinoma of salivary gland origin","volume":"213","author":"Baghai","year":"2017","journal-title":"Pathol Res Pract"},{"key":"R16-20230922","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1177\/1066896917709350","article-title":"Salivary gland secretory carcinoma with high-grade transformation, CDKN2A\/B loss, distant metastasis, and lack of sustained response to crizotinib","volume":"25","author":"Cipriani","year":"2017","journal-title":"Int J Surg Pathol"},{"key":"R17-20230922","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1093\/annonc\/mdw042","article-title":"What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC)","volume":"27","author":"Drilon","year":"2016","journal-title":"Ann Oncol"},{"key":"R18-20230922","first-page":"9008","article-title":"Mammary analog secretory carcinoma of salivary gland with high-grade histology arising in hard palate, report of a case and review of literature","volume":"7","author":"Luo","year":"2014","journal-title":"Int J Clin Exp Pathol"},{"key":"R19-20230922","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/PAS.0000000000000088","article-title":"Mammary analogue secretory carcinoma of salivary glands with high-grade transformation: report of 3 cases with the ETV6-NTRK3 gene fusion and analysis of TP53, beta-catenin, EGFR, and CCND1 genes","volume":"38","author":"Sk\u00e1lov\u00e1","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"R20-20230922","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/his.13268","article-title":"A case of primary secretory carcinoma of the thyroid with high-grade features","volume":"71","author":"Wu","year":"2017","journal-title":"Histopathology"},{"key":"R21-20230922","article-title":"Sinonasal secretory carcinoma of salivary gland with high grade transformation: a case report of this under-recognized diagnostic entity with prognostic and therapeutic implications","author":"Xu","year":"2017","journal-title":"Head Neck Pathol"},{"key":"R22-20230922","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.pharmthera.2017.02.006","article-title":"Targeting TRK family proteins in cancer","volume":"173","author":"Khotskaya","year":"2017","journal-title":"Pharmacol Ther"},{"key":"R23-20230922","first-page":"1","article-title":"Successful targeted therapy of refractory pediatric ETV6-NTRK3 fusion-positive secretory breast carcinoma","volume":"1","author":"Shukla","year":"2017","journal-title":"JCO Precision Oncology"},{"key":"R24-20230922","doi-asserted-by":"crossref","first-page":"CT008","DOI":"10.1158\/1538-7445.AM2016-CT008","article-title":"Abstract CT008: clinical safety and activity from a phase I study of LOXO-101, a selective TRKA\/B\/C inhibitor, in solid-tumor patients with NTRK gene fusions","volume":"76","author":"Hong","year":"2016","journal-title":"Cancer Res"},{"key":"R25-20230922","doi-asserted-by":"crossref","first-page":"CT007","DOI":"10.1158\/1538-7445.AM2016-CT007","article-title":"Abstract CT007: Entrectinib, an oral pan-Trk, ROS1, and ALK inhibitor in TKI-na\u00efve patients with advanced solid tumors harboring gene rearrangements: updated phase I results","volume":"76","author":"Drilon","year":"2016","journal-title":"Cancer Res"},{"key":"R26-20230922","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1097\/PAS.0000000000000392","article-title":"Mammary analogue secretory carcinoma of salivary glands: a clinicopathologic and molecular study including 2 cases harboring ETV6-X fusion","volume":"39","author":"Ito","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"R27-20230922","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/PAS.0000000000000537","article-title":"Mammary analogue secretory carcinoma of salivary glands: molecular analysis of 25 ETV6 gene rearranged tumors with lack of detection of classical ETV6-NTRK3 fusion transcript by standard RT-PCR: report of 4 cases harboring ETV6-X gene fusion","volume":"40","author":"Sk\u00e1lov\u00e1","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"R28-20230922","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1097\/PAS.0000000000000972","article-title":"Molecular profiling of mammary analog secretory carcinoma revealed a subset of tumors harboring a novel ETV6-RET translocation: report of 10 cases","volume":"42","author":"Sk\u00e1lov\u00e1","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"R29-20230922","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/nbt.2696","article-title":"Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing","volume":"31","author":"Frampton","year":"2013","journal-title":"Nat Biotechnol"},{"key":"R30-20230922","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1016\/j.humpath.2013.03.017","article-title":"Utility of mammaglobin immunohistochemistry as a proxy marker for the ETV6-NTRK3 translocation in the diagnosis of salivary mammary analogue secretory carcinoma","volume":"44","author":"Bishop","year":"2013","journal-title":"Hum Pathol"},{"key":"R31-20230922","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/jop.12226","article-title":"A comparative immunohistochemistry study of diagnostic tools in salivary gland tumors: usefulness of mammaglobin, gross cystic disease fluid protein 15, and p63 cytoplasmic staining for the diagnosis of mammary analog secretory carcinoma?","volume":"44","author":"Projetti","year":"2015","journal-title":"J Oral Pathol Med"},{"key":"R32-20230922","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1177\/1066896916670005","article-title":"Combined DOG1 and mammaglobin immunohistochemistry is comparable to ETV6-breakapart analysis for differentiating between papillary cystic variants of acinic cell carcinoma and mammary analogue secretory carcinoma","volume":"25","author":"Said-Al-Naief","year":"2017","journal-title":"Int J Surg Pathol"},{"key":"R33-20230922","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/modpathol.2015.64","article-title":"Mammary analog secretory carcinoma, low-grade salivary duct carcinoma, and mimickers: a comparative study","volume":"28","author":"Stevens","year":"2015","journal-title":"Mod Pathol"},{"key":"R34-20230922","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/nrc3205","article-title":"Targeting MET in cancer: rationale and progress","volume":"12","author":"Gherardi","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"R35-20230922","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1158\/1078-0432.CCR-08-1306","article-title":"Novel therapeutic inhibitors of the c-Met signaling pathway in cancer","volume":"15","author":"Eder","year":"2009","journal-title":"Clin Cancer Res"},{"key":"R36-20230922","first-page":"148","article-title":"Targeting MET in cancer therapy","volume":"3","author":"Mo","year":"2017","journal-title":"Chronic Dis Transl Med"},{"key":"R37-20230922","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00428-012-1358-0","article-title":"Aberrations of MET are associated with copy number gain of EGFR and loss of PTEN and predict poor outcome in patients with salivary gland cancer","volume":"462","author":"Ach","year":"2013","journal-title":"Virchows Arch"},{"key":"R38-20230922","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jtho.2016.10.014","article-title":"Targeting MET in lung cancer: will expectations finally be MET?","volume":"12","author":"Drilon","year":"2017","journal-title":"J Thorac Oncol"},{"key":"R39-20230922","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/modpathol.2017.127","article-title":"Recurrent EML4-NTRK3 fusions in infantile fibrosarcoma and congenital mesoblastic nephroma suggest a revised testing strategy","volume":"31","author":"Church","year":"2018","journal-title":"Mod Pathol"},{"key":"R40-20230922","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.leukres.2012.04.010","article-title":"ETV6 fusion genes in hematological malignancies: a review","volume":"36","author":"De Braekeleer","year":"2012","journal-title":"Leuk Res"},{"key":"R41-20230922","first-page":"5046","article-title":"ETV6-NTRK3 gene fusions and trisomy 11 establish a histogenetic link between mesoblastic nephroma and congenital fibrosarcoma","volume":"58","author":"Knezevich","year":"1998","journal-title":"Cancer Res"},{"key":"R42-20230922","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/ng0298-184","article-title":"A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma","volume":"18","author":"Knezevich","year":"1998","journal-title":"Nat Genet"},{"key":"R43-20230922","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S0002-9440(10)65732-X","article-title":"Congenital mesoblastic nephroma t(12;15) is associated with ETV6-NTRK3 gene fusion: cytogenetic and molecular relationship to congenital (infantile) fibrosarcoma","volume":"153","author":"Rubin","year":"1998","journal-title":"Am J Pathol"},{"key":"R44-20230922","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S1535-6108(02)00180-0","article-title":"Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma","volume":"2","author":"Tognon","year":"2002","journal-title":"Cancer Cell"},{"key":"R45-20230922","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1097\/PAS.0000000000000677","article-title":"ETV6-NTRK3 is expressed in a subset of ALK-negative inflammatory myofibroblastic tumors","volume":"40","author":"Alassiri","year":"2016","journal-title":"Am J Surg Pathol"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00000478-201808000-00016","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T22:31:34Z","timestamp":1695421894000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00000478-201808000-00016"}},"subtitle":["Expanding the Molecular Spectrum of a Recently Described Entity"],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":45,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000001065","relation":{},"ISSN":["0147-5185"],"issn-type":[{"value":"0147-5185","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]}}}